These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 34334626)
1. Is there a role for immune-enhancing therapies for acutely ill patients with coronavirus disease 2019? Wittebole X; Montiel V; Mesland JB Curr Opin Crit Care; 2021 Oct; 27(5):480-486. PubMed ID: 34334626 [TBL] [Abstract][Full Text] [Related]
2. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927 [TBL] [Abstract][Full Text] [Related]
3. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial. Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671 [TBL] [Abstract][Full Text] [Related]
4. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308 [TBL] [Abstract][Full Text] [Related]
5. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial. Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T; Trials; 2021 May; 22(1):343. PubMed ID: 34001215 [TBL] [Abstract][Full Text] [Related]
6. Immune-Based Therapy for COVID-19. Esmaeilzadeh A; Jafari D; Tahmasebi S; Elahi R; Khosh E Adv Exp Med Biol; 2021; 1318():449-468. PubMed ID: 33973194 [TBL] [Abstract][Full Text] [Related]
7. Hyperimmune anti-COVID-19 IVIG (C-IVIG) Therapy for Passive Immunization of Severe and Critically Ill COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial. Ali S; Luxmi S; Anjum F; Muhaymin SM; Uddin SM; Ali A; Ali MR; Tauheed S; Khan M; Bajwa M; Baig SU; Shalim E; Ahmed I; Khan AS; Quraishy S Trials; 2020 Nov; 21(1):905. PubMed ID: 33138867 [TBL] [Abstract][Full Text] [Related]
8. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial. Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ Trials; 2021 May; 22(1):342. PubMed ID: 34001174 [TBL] [Abstract][Full Text] [Related]
9. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Chai KL; Valk SJ; Piechotta V; Kimber C; Monsef I; Doree C; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N Cochrane Database Syst Rev; 2020 Oct; 10():CD013600. PubMed ID: 33044747 [TBL] [Abstract][Full Text] [Related]
10. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of COVID-19 convalescent plasma in severe pulmonary disease: A report of 17 patients. Pal P; Ibrahim M; Niu A; Zwezdaryk KJ; Tatje E; Robinson WR; Ko L; Satyavarapu I; Jones WE; Nachabe A; Luk A; Mushatt DM; Halvorson K; Denson JL; Smith CC; Simeone F; Davis G; Gill SK; McDougal A; Vigh AS; Peterson TG; Ning B; Hu T; Socola F; Robinson J; Safah H; Saba NS Transfus Med; 2021 Jun; 31(3):217-220. PubMed ID: 33073895 [No Abstract] [Full Text] [Related]
12. Cytosorb filter: An adjunct for survival in the COVID-19 patient in cytokine storm? a case report. Rizvi S; Danic M; Silver M; LaBond V Heart Lung; 2021; 50(1):44-50. PubMed ID: 33041058 [TBL] [Abstract][Full Text] [Related]
13. Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma. Lindholm PF; Ramsey G; Kwaan HC Semin Thromb Hemost; 2020 Oct; 46(7):796-803. PubMed ID: 32526774 [TBL] [Abstract][Full Text] [Related]
14. Application of extracorporeal therapies in critically ill COVID-19 patients. Zhou Z; Kuang H; Ma Y; Zhang L J Zhejiang Univ Sci B; 2021 Sept 15; 22(9):701-717. PubMed ID: 34514751 [TBL] [Abstract][Full Text] [Related]
15. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients. Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172 [TBL] [Abstract][Full Text] [Related]
16. Convalescent plasma in Covid-19: Possible mechanisms of action. Rojas M; Rodríguez Y; Monsalve DM; Acosta-Ampudia Y; Camacho B; Gallo JE; Rojas-Villarraga A; Ramírez-Santana C; Díaz-Coronado JC; Manrique R; Mantilla RD; Shoenfeld Y; Anaya JM Autoimmun Rev; 2020 Jul; 19(7):102554. PubMed ID: 32380316 [TBL] [Abstract][Full Text] [Related]
17. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Bégin P; Callum J; Heddle NM; Cook R; Zeller MP; Tinmouth A; Fergusson DA; Cushing MM; Glesby MJ; Chassé M; Devine DV; Robitalle N; Bazin R; Shehata N; Finzi A; McGeer A; Scales DC; Schwartz L; Turgeon AF; Zarychanski R; Daneman N; Carl R; Amorim L; Gabe C; Ellis M; Sachais BS; Loftsgard KC; Jamula E; Carruthers J; Duncan J; Lucier K; Li N; Liu Y; Armali C; Kron A; Modi D; Auclair MC; Cerro S; Avram M; Arnold DM Trials; 2021 May; 22(1):323. PubMed ID: 33947446 [TBL] [Abstract][Full Text] [Related]
18. [Successful administration of convalescent plasma in critically ill COVID-19 patients in Hungary: the first two cases]. Bobek I; Gopcsa L; Réti M; Bekő G; Hancz L; Lakatos B; Molnár E; Nagy S; Reményi P; Sebestyén G; Sinkó J; Szlávik J; Szolnoky M; Vályi-Nagy I Orv Hetil; 2020 Jul; 161(27):1111-1121. PubMed ID: 32564002 [TBL] [Abstract][Full Text] [Related]
19. Compassionate Use of GC5131 (Hyperimmunoglobulin) Therapy in Critically Ill Patients Diagnosed with COVID-19: A Case Series and Review of Literature. Choi S; Hwang S; Kwon K Viruses; 2021 Sep; 13(9):. PubMed ID: 34578407 [TBL] [Abstract][Full Text] [Related]
20. How should we use convalescent plasma therapies for the management of COVID-19? Wood EM; Estcourt LJ; McQuilten ZK Blood; 2021 Mar; 137(12):1573-1581. PubMed ID: 33202419 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]